Soleno Therapeutics (SLNO) surged 32.31% to close at $52.26 on Monday, following an all-cash acquisition offer from Neurocrine Biosciences (NBIX) at $53 per share. The deal has sparked significant interest, with trading volume hitting 58 million shares—over 2,100% above its three-month average. Investors are now closely monitoring potential regulatory hurdles and the deal’s closing timeline.
The acquisition is strategic for Neurocrine, bolstering its rare-disease drug portfolio with Soleno’s VYKAT XR treatment for hyperphagia in Prader-Willi Syndrome, the only FDA-approved option for this condition. VYKAT XR has shown promising sales growth, generating $92 million in its latest quarter alone. With Neurocrine’s robust cash position of $2.5 billion, the $2.9 billion acquisition is manageable and could enhance its long-term growth prospects, especially given VYKAT XR’s intellectual property extending into the 2040s.
For market professionals, Neurocrine’s valuation at 18 times free cash flow makes it a compelling stock to monitor as the acquisition progresses, potentially unlocking further value in the biotech sector.
Source: fool.com